Plain-English translation of NCT06493864 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medicine called , an antibody designed to help fight advanced cancer. Researchers want to find the right dose of this medication and see how safe it is and whether it helps people with breast cancer or other solid tumors that have spread or cannot be surgically removed. The study will enroll about 21 people.
Many people with advanced breast cancer and other solid tumors don't have enough treatment options left after standard therapies stop working. This medication offers a new approach that researchers hope could help these patients.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an intravenous infusion (through an IV into your vein) in a 3-week cycle. If the treatment is helping and you are tolerating it well, you can continue with additional cycles. Researchers will monitor you closely for side effects, check how your body is responding to the medicine, and watch how your tumors are changing. The study will end if your cancer worsens, side effects become too difficult to manage, or for other medical reasons.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
China